Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr
News

Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr

The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024

  • By IPP Bureau | November 05, 2024

Gland Pharma Limited has reported consolidated financial results for the period ended September 30, 2024.

The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024 as compared to Rs. 1,453.13 crores during the period ended June 30, 2024. The company reported total income of Rs.1, 426.57 crores during the period ended September 30, 2023.

The company has posted net profit of Rs. 163.53 crores for the period ended September 30, 2024 as against net profit of Rs. 143.76 crores for the period ended June 30, 2024. The company posted net profit of Rs. 194.08 crores for the period ended September 30, 2023.

For the Half Year ended FY2025, Gland Pharma has reported total income of Rs. 2,918.62 crores as compared to Rs. 2,672.81 crores during the 6 months period ended September 30, 2023.

The company has posted net profit of Rs. 307.29 crores for the 6 months period ended September 30, 2024 as against net profit of Rs. 388.184 crores for the 6 months period ended September 30, 2023.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International